Financing and going-concern risk
Operations depend on external capital until operating cash generation improves.
- Scope
- Liquidity and dilution
- Materiality
- high
Pure Bioscience, Inc.
PURE Bioscience, Inc. develops and commercializes antimicrobial products based on patented stabilized ionic silver technology. Its core offerings use Silver Dihydrogen Citrate (SDC) in liquid formulations for sanitation, disinfection, and food-safety applications, and the company also supplies SDC-based ingredients for personal care uses.
−103,3 %
59,3 %
−109,1 %
+12,4 %
1.12
0.97
| % | |
|---|---|
| Food safety sanitizers and disinfectants | 60% EPA/FDA/Health Canada-registered SDC products used on food-contact surfaces and in processing environments. |
| Direct food-contact processing aids | 20% SDC formulations used in food processing applications where direct contact is permitted. |
| Raw material ingredients | 10% SDC supplied as an ingredient for third-party personal care and related formulations. |
| Contract manufacturing | 10% Manufacture and sale of SDC-based products for end use or as manufacturing inputs. |
PURE sells to food-industry end users that need antimicrobial control across production, handling, and transport...
- Restaurant chainsprimary
Buy food-contact surface sanitizer/disinfectant for hygiene and compliance.
- Food processorsprimary
Use PURE Control and related SDC products in processing environments.
- Food manufacturerssecondary
Purchase antimicrobial products to support sanitation and food safety.
- Food transportation companiessecondary
Use sanitizing products for surfaces and handling equipment in transit.
- Distributorsprimary
Buy and resell SDC products to extend market reach and local coverage.
- Personal care formulatorsemerging
Source SDC as a raw ingredient for third-party product formulations.
PURE is a U.S.-based company and its registered products are cleared for use in the United States, with additional...
- •United States is the core operating and sales market
- •Canada is an approved market through Health Canada registration
- •Distribution partners help extend reach across U.S. regions
- •International expansion depends on third-party approvals
- •Regulatory status by country affects where products can be sold
PURE’s strategy centers on commercializing its SDC platform in food safety, expanding through distributors, and adding...
01
Grow the distribution networkshort-term
Distributors extend reach, reduce logistics burden, and speed market access.
02
Pursue approvals and partnerships outside the U.S.medium-term
International approvals can open new markets without building a full direct-sales footprint.
03
Develop new proprietary products and applicationsmedium-term
New formulations can broaden the platform beyond current food-safety uses.
04
Protect intellectual propertylong-term
Patent protection supports differentiation and helps defend the SDC platform.
PURE faces commercialization risk because its products must gain broader acceptance in a competitive food-safety market...
Limited market acceptance of SDC products
Customers may not adopt the products broadly despite efficacy benefits.
- Scope
- Food safety market
- Materiality
- high
Intense competition from larger food-safety companies
Rivals have broader product lines, stronger brands, and more resources.
- Scope
- Food safety and sanitation products
- Materiality
- high
Regulatory approval delays
Sales depend on EPA, FDA, Health Canada, and other approvals.
- Scope
- Product registration and market entry
- Materiality
- high
Intellectual property protection risk
The platform depends on patents and proprietary formulations for differentiation.
- Scope
- Patent claims and enforcement
- Materiality
- medium
Revenue recognition timing
Quarterly revenue comparability
Deferred revenue
Balance sheet liabilities and future revenue conversion
Inventory and manufacturing cost allocation
Gross margin and inventory valuation
R&D and product registration costs
Operating expense volatility
Going-concern assessment
Financial statement presentation and risk disclosure
: 29.4.2026